Answers are grounded in this paper and cite their sources.
Case report reveals false-positive fentanyl result in a woman treated with paliperidone, indicating the need for cautious interpretation of drug screens.
Fentanyl is a potent synthetic opioid frequently included in rapid urine drug-screening panels to detect opioid misuse. However, immunoassay-based screening tests may yield false-positive results due to cross-reactivity with non-opioid medications. Previous case reports have described false-positive fentanyl results in patients treated with risperidone, and one laboratory study demonstrated direct cross-reactivity between 9-hydroxyrisperidone—the active metabolite of risperidone and the main compound of paliperidone—and fentanyl immunoassays. We report the case of a 31-year-old woman, admitted for a first psychotic episode, who was receiving treatment with paliperidone and screened positive for fentanyl in a urine immunoassay performed as part of a research protocol. Subsequent confirmatory testing by liquid chromatography–tandem mass spectrometry (LC–MS/MS) revealed no fentanyl or metabolites, confirming a false-positive result most likely due to paliperidone-related cross-reactivity. To our knowledge, this represents the first published case of a false-positive fentanyl immunoassay associated with paliperidone treatment, consistent with prior evidence of interference from structurally related antipsychotics. This case highlights the importance of clinician awareness of the limitations of rapid urine drug screens, particularly in vulnerable psychiatric populations where unwarranted suspicion of substance misuse may erode therapeutic trust and lead to medico-legal consequences.
No takes yet. Share an insight, caveat, or question.
Mana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: